Clinical trial
A Phase I - II Safety Study of Filgrastim (Neupogen) to Improve Left Ventricular…
NCT00215124 · The Cleveland Clinic, Other · Completed
Key facts
| NCT number | NCT00215124 |
|---|---|
| Title | A Phase I - II Safety Study of Filgrastim (Neupogen) to Improve Left Ventricular Function After Severe Acute Myocardial Infarction |
| Official title | Phase I - II Safety Study of Filgrastim (Neupogen) to Improve Left Ventricular Function After Severe Acute Myocardial Infarction |
| Lead sponsor | The Cleveland Clinic, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myocardial Infarction |
| Intervention type | Drug |
| Interventions | Filgrastim |
| Completion | Feb 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Sep 19, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: